Editors Choice
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
This phase I study evaluated nivolumab combined with erlotinib in patients with advanced EGFR-mutant NSCLC.
The content on this site is intended for healthcare professionals.
Copyright © 2023 Elsevier Inc. except certain content provided by third parties.
